N aïve, activated and memory T cells display differences in their ability to respond to antigen. These include changes in proliferation, survival, sensitivity to antigen, dependence on costimulatory signals and alterations in T cell homing 1 . Cytokines responsible for the control of these activities often signal through receptor-associated Janus kinases (Jak proteins) that regulate cytoplasmic transcription factors termed signal transducers and activators of transcription (STAT) 2 . Thus, the Jak-STAT pathway senses and interprets environmental signals essential for proliferation and functional identity 2 . Here, we examined whether cytokine cues delivered by the Jak-STAT pathway can be adapted to fine-tune the effector properties of individual CD4 + T cell subsets. Studies of infection, inflammation, autoimmunity and cancer demonstrate that the cytokine IL-6 is essential for the generation of adaptive immunity 3 . Activities include the maturation and maintenance of antibody-secreting B cells, and responses that shape the effector characteristics of CD4
+ helper T cells (T H ) 3 . In this regard, mice lacking IL-6 often show deficiencies in T cell effector function and memory recall [4] [5] [6] [7] [8] [9] . Studies also suggest that CD4 + T cells display differences in IL-6 responsiveness that may reflect the activation status of the T cell 7, [10] [11] [12] . How these differences arise is currently unclear. The receptor complex responsible for IL-6 signaling consists of a type-1 cytokine receptor (IL-6R, CD126) and a signal-transducing β-receptor (gp130, CD130) subunit 3 . IL-6R is shed in response to
CD4
+ T cell activation, and inflammatory T cells from sites of disease often display low IL-6R expression 7, 10, [12] [13] [14] [15] [16] [17] . IL-6 activates the latent transcription factors STAT1 and STAT3 (ref. 3 ). IL-6 control of STAT3 is essential for T cell recruitment and survival and maintenance of activated T cells within inflamed tissues 11, 14, 16 . These STAT3-driven responses include the transactivation of anti-apoptotic regulators and genes that determine the effector or regulatory characteristic of CD4 + T cells 3, 11, 18 . In contrast, IL-6 activation of STAT1 plays a more regulatory role and often determines the transcriptional output of STAT3 (refs. [18] [19] [20] [21] ). These studies illustrate a complex interplay between STAT1 and STAT3 and emphasize how STAT1 signaling may shape the biological properties of IL-6 (refs. 18, [20] [21] [22] [23] [24] ). Notably, CD4
+ T cell activation has been shown to alter IL-6 signaling through STAT1 (refs. 9, 11 ). Here we show that STAT1 phosphorylation in response to IL-6 is suppressed in activated and memory CD4
+ T cells and identify protein tyrosine phosphatases as regulators of STAT1 activity. Our data further showed how this reprogramming mechanism may influence the way effector memory CD4
+ T cells sense and interpret IL-6 signals in disease.
Results

Infiltrating synovial CD4 + T cells have altered IL-6-mediated STAT1 activation. Previous studies suggest that CD4
+ T cell activation alters cytokine signaling through the Jak-STAT pathway 4, 9, 11 . 
Activation of naïve CD4
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To further these findings, we established antigen-induced arthritis (AIA) in C57BL/6 wild-type mice through immunization with methylated BSA (mBSA). Histological joint sections from day 10 of AIA were evaluated for tyrosine-phosphorylated STAT1 and STAT3 (hereafter pY-STAT1 and pY-STAT3) using immunofluorescence (Fig. 1a) . Whereas pY-STAT3 colocalized with CD3 + T cells, pY-STAT1 showed weak colocalization with the CD3 stain (Fig. 1a) . To verify these observations, CD4
+ T cells were isolated at day 10 of AIA from the inflamed synovium of wild-type mice and stimulated ex vivo with IL-6 (20 ng/ml). Intracellular flow cytometry showed that synovial CD4 + T cells displayed reduced pY-STAT1 staining compared with IL-6-treated CD4
hi naïve T cells (T N cells) from the spleen of wild-type mice (Fig. 1b) . Both CD4 + T cell populations displayed comparable pY-STAT3 responses to IL-6 (Fig. 1b) . To test whether prior antigenic challenge with mBSA restricted the ability of IL-6 to signal through STAT1, we extracted total CD4 + T cells from the inguinal draining lymph nodes of wild-type mice immunized with mBSA, stimulated them ex vivo for 30 min with 20 ng/ml IL-6 and monitored changes in pY-STAT1 and pY-STAT3 by intracellular flow cytometry. Compared with wild-type CD4 + T cells from the inguinal lymph node of non-challenged mice, CD4
+ T cells from mBSA-immunized mice showed impaired pY-STAT1 detection in response to IL-6 (Fig. 1c) . This reduction in pY-STAT1 was particularly evident in activated or memory CD4
+ T cells (Fig. 1c ). STAT1 is an important determinant of T cell effector function [20] [21] [22] . We therefore used quantitative PCR to evaluate the effector characteristics of CD4 + T cells from wild-type mice with AIA. Analysis was performed on CD4 + T N cells and
int-hi effector memory T cells (T EM cells) from the inguinal lymph nodes of wild-type mice with AIA. Ahr, Il21, Rorgt, Il17a, Ifnγ and Stat3 were all highly expressed in CD4
+ T EM cells compared with CD4 + T N cells (Fig. 1d ). In contrast, the expression of Socs3, a negative regulator of Jak-STAT signaling, remained comparable in both CD4 + T cell populations (Fig. 1d) . Additionally, intracellular cytokine staining of CD4 + T N and CD4
+ T EM cells showed that CD4 + T EM cells generated increased amounts of IL-21 ( Fig. 1e and Supplementary Fig. 1a) . Thus, CD4 + T N and CD4
+ T EM cells showed differences in IL-6 responsiveness.
Control of STAT1 activity is not determined by IL-6R signaling in CD4
+ T cells. To determine whether T cell subsets display different IL-6 signaling properties, we purified splenic CD4 + T N cells, CD4
cells (T Eff cells) and CD4
+ T EM cells from wild-type mice. These populations showed differences in IL-6R and gp130 expression, but displayed a similar transient activation of pY-STAT3 in response to IL-6 ( Fig. 2a and Supplementary Fig. 1b) . A strong induction of pY-STAT1 was observed in IL-6-treated CD4 + T N cells, whereas CD4
+ T CM , T Eff and T EM cells showed impaired pY-STAT1 activation (Fig. 2a) . A similar regulation of pY-STAT1 was also observed in human CD4
+ T cells ( Supplementary Fig. 1c ). Given that activation-induced shedding of IL-6R may affect IL-6 receptor signaling, we investigated the IL-6 control of pY-STAT1 and pY-STAT3 in splenic CD4 + T N , T CM , T Eff and T EM cells from wild-type and Il6ra −/− mice. IL-6 signaling in Il6ra −/− CD4 + T cells was triggered by IL-6 trans-signaling using an IL-6-sIL-6R chimeric fusion protein (HDS) 7, 8 . Il6ra −/− CD4 + T cells were not activated by IL-6 alone, but responded to an equimolar concentration of HDS, and all Il6ra −/− CD4 + T cells showed increased pY-STAT3 after HDS stimulation (Fig. 2b) . Whereas HDS induced pY-STAT1 in Il6ra
CD4
+ T N cells, changes in pY-STAT1 were not seen in HDS-treated CD4 + T CM , T Eff and T EM cells from Il6ra −/− mice (Fig. 2b) . Thus, the loss of STAT1 signaling in activated CD4
+ T cells is independent of changes in IL-6R regulation. A similar pattern of pY-STAT1 regulation was noted in wild-type CD4 + T cells stimulated with IL-27 or IFNγ ( Fig. 2c and Supplementary Fig. 2d ), suggesting that the control of STAT1 phosphorylation was not unique to IL-6.
TCR activation regulates IL-6R signaling in CD4
+ T cells. To investigate whether prior TCR engagement contributed to the changes in STAT1 phosphorylation in activated or memory CD4
+ T cells, we compared IL-6 signaling in CD4 + T N cells and CD4 + T cells previously activated with antibodies to CD3 and CD28. Wild-type CD4 + T N cells were cultured for 72 h with antibodies to CD3 and CD28, then cultured for 48 h in fresh media, without exogenous stimulation ( Supplementary Fig. 2a ). This rest period restored the surface expression of IL-6R on these TCR-experienced effector-like CD4 + T cells (T EXP cells; Supplementary Fig. 2a) . Whereas IL-6 stimulation of CD4
+ T EXP cells induced pY-STAT3, the activation of pY-STAT1 was minimal compared with the IL-6-dependent induction of pY-STAT1 in CD4
+ T N cells ( Supplementary Fig. 2b,c) , thus indicating that CD4 + T cell activation altered the subsequent activation of STAT1 by IL-6. To test whether TCR signaling altered the IL-6-induced activation of STAT1, we generated CD4 + T EXP cells from wild-type CD4 + T N cells using varying concentrations of costimulatory antibodies to CD3 (0.1-10 μg/ml) and CD28 (0.5-15 μg/ml) ( Supplementary  Fig. 3a ) and stimulated the expanded CD4 + T EXP cells with IL-6. The IL-6-dependent induction of pY-STAT3 was not affected by differences in antibody concentration. However, the suppression of pY-STAT1 in response to IL-6 was sensitive to treatment with antibody to CD3 (anti-CD3), with increasing doses of antibody leading to repression of pY-STAT1 ( Supplementary Fig. 3a) . Thus, TCR signaling affected the inhibition of pY-STAT1 by IL-6.
We next determined whether changes in STAT1 activation altered the transcriptional output of IL-6. CD4 + T N , T EXP and T EM cells were stimulated for 6 h with IL-6, then subjected to transcriptomic analysis. This time point was selected based on the temporal profile of pY-STAT1 and pY-STAT3 detection (Fig. 2a) , and the optimal expression of STAT-target genes (Ahr, Bcl3, Bcl6, Kat2b, Il10, Il21, Pim1, Stat3), as determined via qPCR ( Supplementary  Fig. 3b) Supplementary Fig. 3c ). The number of transcripts enhanced by IL-6 in CD4
+ T EXP cells (236) was markedly reduced when compared with the IL-6-dependent induction of transcripts in CD4 + T N cells (509) (Fig. 2e) . The inclusion of costimulatory antibodies to CD3 and CD28 further suppressed the number of genes induced by IL-6 in CD4
+ T EXP cells (26) , which revealed the capacity of TCR activation to replace the signal delivered by IL-6 ( Fig. 2e and Supplementary Fig. 3d ). Thus, IL-6 controls distinct patterns of gene regulation in CD4 + T N , T EXP and T EM cells that may shape the functional properties of these CD4 + T cells.
STAT1 phosphorylation is regulated by PTPN2.
We next determined whether TCR activation altered the expression of genes linked with IL-6 receptor signaling in CD4 + T N , T EXP and T EM cells. No significant differences in the expression of IL-6 receptor subunits (Il6ra, Il6st), Janus kinases (Jak1, Jak2, Tyk2), STATs (Stat1, Stat3, Stat5a, Stat5b) and regulators of IL-6 or Jak-STAT signaling (Socs1, Socs3, Pias1, Dusp2, Cish, Arid5a, Arid5b) were observed between these CD4 + T cells ( Supplementary Fig. 4a ). Thus, the immediate regulation of STAT1 activity in CD4 + T EXP cells and CD4 + T EM cells was not attributed to changes in the makeup of the IL-6 signaling cascade.
To examine how CD4 + T cell activation affected STAT1 signaling we assessed IL-6 responses in wild-type CD4 + T N and T EM cells using antibodies for serine phosphorylated STAT1 and STAT3 (hereafter pS-STAT1 and pS-STAT3). Intracellular flow cytometry 
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showed that the IL-6 activation of pS-STAT1 and pS-STAT3 was comparable in both CD4 + T cells (Fig. 3a) . However, CD4 + T EM cells showed suppressed pY-STAT1 in response to IL-6 ( Fig. 3a and Supplementary Fig. 1c ). We therefore considered whether protein phosphatases controlled the tyrosine phosphorylation of STAT1.
Treatment of CD4
+ T N and T EM cells with the protein tyrosine phosphatase inhibitor sodium orthovanadate reversed the loss of pY-STAT1 activation in IL-6-stimulated CD4 + T EM cells (Fig. 3a) . IL-6 control of pY-STAT3 was unaltered by sodium orthovanadate (Fig. 3a) . Analysis of Ahr, Il21, Socs3 and Stat3 expression in IL-6-treated CD4 + T EM cells showed that the inclusion of sodium orthovanadate reduced expression of Il21 and Socs3 (Fig. 3b) . Thus, protein tyrosine phosphatase activity appears to be integral to the IL-6 control of STAT1 in CD4 + T EM cells. To identify protein tyrosine phosphatases responsible for the regulation of STAT1 in CD4 + T EXP and T EM cells, we compared transcriptomic data from CD4 + T N , T EXP and T EM cells activated with costimulatory antibodies to CD3 and CD28. Several protein phosphatases were more highly expressed in CD4 + T EXP and T EM cells than CD4
+ T N cells, including the protein tyrosine phosphatases Ptpn2 and Ptpn22 (Fig. 3c) .
Flow cytometry analysis showed that PTPN2 was more highly expressed in CD4
+ T EM cells than CD4 + T N cells (Fig. 4a ). Il6ra
cells had comparable expression of PTPN2 to that of wild-type CD4
+ T EM cells (Fig. 4b ), indicating that PTPN2 expression was independent of IL-6 signaling. To confirm the relevance of these findings to pathology, we conducted immunohistochemistry of joint tissue from wild-type mice with AIA. Synovial CD3 + T cells showed enhanced expression of PTPN2 and low pY-STAT1 staining (Fig. 4c) . Similarly, flow cytometry of IL-6-stimulated CD4
+ T EM cells revealed that PTPN2 expression correlated with suppression of pY-STAT1 ( littermates or wild-type mice ( Fig. 4e and Supplementary Fig. 4c ). Moreover, ImageStream analysis showed the colocalization of PTPN2 with non-phosphorylated STAT1 in wild-type CD4 + T EM cells (Fig. 4f) . Thus, PTPN2, and to a lesser extent PTPN22, regulates STAT1 signaling in activated and memory CD4 + T cells.
T cell activation retunes the transcriptional output of IL-6 in CD4 + T EM cells. Next, we compared the transcriptional output of IL-6 in CD4 + T N , T EXP and T EM cells. Analysis was confined to significantly regulated genes (P < 0.05) that displayed both a relative signal intensity of >150 and >1.5-fold alteration in expression. Circos visualization identified a number of genes that were under 
Relative expression (z score) 
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NATure ImmuNoLogy IL-6 control in CD4 + T N (225), T EXP (31) and T EM (180) cells (Fig. 5a ). Hierarchical clustering and validation of selected gene targets identified IL-6 gene signatures that were either common to all three CD4 + T cell subsets or uniquely expressed by a particular population (Supplementary Fig. 3c) . Genes regulated by IL-6 in CD4 + T N , T EXP and T EM cells were mainly STAT3 target genes 23, 24 and included genes that encoded transcriptional regulators (for example, Bcl3, Bcl6, Etv6), co-repressors (for example, Sbno2, Muc1) and negative regulators of transcription factors such as STAT3, NF-κB and AP1 (for example, Socs3, Pim1, Batf) ( Supplementary Fig. 3c ).
Next, we conducted a molecular pathway analysis of the transcriptomic data from IL-6-treated CD4 + T N , T EXP and T EM cells (Fig. 5b) . We also mapped these datasets against publicly available transcriptomic data from IL-6-stimulated Stat1 −/− and Stat3 20 ( Fig. 5c ). This analysis identified a series of STAT1-regulated genes commonly associated with interferon signaling (for example, Irf8, Gbp2, Gbp5, Gbp6, Stat1, Parp9). In contrast, STAT3-regulated genes displayed greater functional diversity and were implicated in interleukin signaling, immune activation, proliferation, catabolism and metabolism (for example, Socs3, Bcl3, Il6r, Kat2b) (Fig. 5b,c) . This collective approach demonstrated that STAT1 and STAT3 regulated distinct patterns of gene expression in IL-6-stimulated CD4 + T N , T EXP and T EM cells (Fig. 5b,c) . For example, compared with IL-6-stimulated CD4 + T N cells, activation with IL-6 enhanced the expression of genes associated with prolonged lymphocyte survival and memory (for example, Hmox1, Myc, Cd83) and regulatory (for example, Lag3, Il10, Foxp3) or effector (for example, Ahr, Il21, Ifng) characteristics in CD4 + T EM cells. We next performed ChIP-seq in IL-6-stimulated CD4 + T N and T EM cells. Sequencing peaks displaying a four-fold increase above input (P < 0.0001; false discovery rate (FDR) 0.05) were aligned to the genome and assigned to transcription start sites (TSSs), exons and introns ( Fig. 6 and Supplementary Fig. 5 ). Peaks located in undefined intergenic regions were excluded from the analysis. ChIP-seq of IL-6-stimulated CD4 + T N cells identified 1,625 peaks associated with STAT1 and 602 peaks for STAT3 (Fig. 6a) . The numbers of STAT1 (446) and STAT3 (552) peaks were reduced in CD4 + T EM cells (Fig. 6a) . To understand the regulatory properties of STAT1 and STAT3, we first confined our analysis to peaks residing within TSSs (Fig. 6b and Supplementary Fig. 5 ). Sequencing peaks that mapped to defined gene promoters were correlated against corresponding transcriptomic data from IL-6-treated CD4 + T N and T EM cells (Fig. 6c and Supplementary Fig. 5 ). STAT1 and STAT3 showed substantially reduced binding to TSS regions in CD4 + T EM cells compared with CD4 + T N cells (Fig. 6b-d) . Few genes shared STAT1 and STAT3 binding (for example, Stat3, Stat5b, Icam1, Socs3, Sigirr, Akt2) (Fig. 6b,d) , and these coregulated genes were largely restricted to CD4 + T N cells (Fig. 6b,d) . Stat3 was the only gene that was bound by both STAT1 and STAT3 in CD4 + T EM cells (Fig. 6c) . To determine the specificity of these DNA-transcription factor interactions, we used computational tools to identify consensus DNA motifs for STAT1 and STAT3 binding (Supplementary Fig. 5c ). Analysis of ChIP-seq datasets from IL-6-treated CD4 + T N and T EM cells identified sequences resembling an IFN-regulated STATresponsive element (ISRE; E value 5.9 × 10 -40 ) for STAT1 binding and sequences homologous to a gamma-activated sequence (GAS; E value 1.2 × 10 -115 ) for STAT3 ( Supplementary Fig. 5c ). We also identified consensus motifs for other transcription factors including SP1 and C2H2 zinc-finger transcription factor proteins ( Supplementary  Fig. 5c ) and ChIP-qPCR showed STAT1 and STAT3 bound to SP1 consensus binding sequences ( Supplementary Fig. 5d and Supplementary Table 2 ). Thus, transcriptional differences between IL-6-stimulated CD4 + T N and T EM cells are shaped by STAT1 and STAT3 docking to both classical STAT-responsive elements and DNA motifs, which would suggest a regulatory interplay with other transcription factors in CD4 + T N and T EM cells.
Genes under IL-6 control in CD4 + T EM cells are regulated at distal promoter regions. Next we investigated the canonical pathways associated with the genes that were bound with STAT1 or STAT3 in IL-6-treated CD4 + T N and T EM cells. Bioinformatic analysis identified a selective enrichment of genes involved in disease processes, catabolism and cytokine signaling in CD4 + T EM cells as compared with CD4
+ T N cells ( Supplementary Fig. 6a and Supplementary Table 3 ). Many of the genes associated with these pathways were distinct from those showing STAT1 or STAT3 binding to TSSs (Fig. 6b) , suggesting that genes under IL-6 regulation in CD4
+ T EM cells may be controlled by STAT1 and STAT3 binding to distal promoter regions. To identify possible mechanisms that may explain this distal regulation, we evaluated whether STAT1 and STAT3 peaks aligned with enhancer regions displaying enriched binding of the histone acetyl-transferase P300 (hereafter P300 enhancer elements [25] [26] [27] [28] ). STAT1 and STAT3 ChIP-seq datasets from IL-6-treated CD4 + T N or T EM cells were mapped against publicly available P300 ChIP-seq data from mouse CD4 + T cells polarized in vitro into T H 1, T H 2 or T H 17 cells 28 ( Supplementary Fig. 6b and Supplementary Table 4) . A combined analysis of IL-6-treated CD4 + T N and T EM cells identified 558 genes that bound P300 in association with either STAT1 or STAT3 (Fig. 7a,b) . In IL-6-stimulated CD4 + T N and T EM cells, we identified 215 genes that displayed alternate binding of STAT1 or STAT3 in CD4 + T N and T EM cells (Fig. 7b) . These genes were selectively induced or repressed by IL-6 in CD4
+ T EM cells ( Fig. 7b and Supplementary Table 5 ). This analysis indicated that genes controlled by IL-6 in CD4 + T N and T EM cells are associated with P300 enhancer elements that are potentially activated or suppressed by changes in the pattern of STAT1 or STAT3 binding.
Among the 215 genes regulated by IL-6 in CD4 + T EM cells, 80 displayed STAT1 or STAT3 binding in ChIP-seq data from IL-6-activated CD4 + T N cells, but not in IL-6-treated CD4 + T EM cells (Fig. 7c) . This finding suggests that the binding of STAT1 or STAT3 to these sites might repress the transactivation of these genes. Computational analysis of the other 135 genes showed that some form of STAT1 or STAT3 binding to P300 enhancer elements was retained in both IL-6-stimulated CD4 + T N and T EM cells ( Fig. 7c  and Supplementary Fig. 6b ). These genes included Il10, Il21, Il21r, Bcl3, Batf, Junb, Socs1 and Cd274 (Fig.7c) . Circos visualization illustrates how the binding of STAT1 and STAT3 to these promoters differed between IL-6-stimulated CD4 + T N and T EM cells (Fig. 7c) . We identified five discrete patterns of STAT1 and STAT3 binding: (Fig.7d ). Computational analysis of the genes affiliated with each pattern revealed links with the cytokine control of T cell proliferation, differentiation and survival (Fig. 7d,  Supplementary Fig. 6b and Supplementary Table 6 ). This was particularly apparent in pattern 2, and to a lesser extent, patterns 3 and 5. Promoter regions assigned to pattern 2 displayed binding of STAT1 and STAT3 in IL-6-stimulated CD4 + T N cells, but showed a loss of STAT1 in IL-6-activated CD4 + T EM cells. Genes identified with this form of STAT regulation included Junb, Il4ra, Cd274 and Socs1 (Fig. 7c and Supplementary Fig. 6b ) and suggested a potential link to the PTPN2 regulation of pY-STAT1. We therefore conducted a ChIP-qPCR analysis of STAT1 binding to the promoters of Junb, Il4ra, Cd274 and Socs1 in IL-6-stimulated Lck-Cre;Ptpn2 (Fig. 7e) . Thus, PTPN2 activity determined STAT1 binding to specific gene promoter regions in IL-6 activated CD4
+ T EM cells.
PTPN2 correlates with indices of synovial pathology in patients with rheumatoid arthritis. Many of the genes identified in IL-6-stimulated CD4 + T EM cells contribute to the generation and maintenance of effector T cells associated with autoimmunity (Supplementary Table 6 ). We therefore investigated the relationship between PTPN2 and PTPN22 and these IL-6-regulated genes in RNA-seq datasets from synovial tissues biopsies of 87 patients with rheumatoid arthritis. Expression of PTPN2 and PTPN22 in these biopsy samples was compared against corresponding histological staining of the inflamed synovium for the lymphocyte markers CD3 and CD20 by immunohistochemistry. Analysis revealed a close correlation between PTPN2 and CD3 and CD20 (Fig. 8a) . This association was particularly evident in synovial biopsies displaying evidence of ectopic lymphoid-like structures (lymphoidrich) and synovitis with a prominent mononuclear cell infiltrate (myeloid-rich) 29 ( Fig. 8b) . In contrast, PTPN22 displayed a more uniform pattern of expression within the inflamed synovium and showed no correlation with lymphocyte markers or the type of synovial pathology (Fig. 8a,b) . To establish a possible link between PTPN2, and the synovial expression of genes controlled by IL-6 in activated or memory CD4 + T cells PTPN2 was compared against the synovial expression of IL21, IL17A, CD274 and SOCS1. Analysis of synovial RNA-seq datasets showed a correlation between PTPN2 and IL21, IL17A, CD274 and SOCS1 (Fig. 8c) . This relationship was particularly evident in both lymphoid-rich and myeloid-rich synovitis (Fig. 8c) . No clear correlation was observed between PTPN22 and these inflammatory markers (Fig. 8c) . Thus, in human synovial pathology, PTPN2 associates with the involvement of lymphocytes in the disease process and corresponds with the expression of several inflammatory mediators linked to the regulation of STAT1 by PTP enzymes.
Discussion
Through analysis of Jak-STAT signaling in CD4 + T N and T EM cells, we identified that protein tyrosine phosphatases induced as a 
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+ T N cell activation altered the transcriptional output of IL-6 in CD4
+ T EM cells. Our investigation showed that inhibition of STAT1 phosphorylation by PTPN2 affected the expression of certain STAT-regulated target genes in activated or memory CD4 + T cells. Thus, protein tyrosine phosphatases have the capacity to modify the way particular T cell subsets sense and interpret common cytokine cues. While the study focused on the biology of IL-6, this mechanism may also shape the transcriptional output of other lymphokines in CD4 + T cells. Protein phosphatases including dual specificity protein phosphatases (DUSPs) and protein tyrosine phosphatases (PTPs) can regulate Jak-STAT signaling 30, 31 . For example, PTPN2 and PTPN11 
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NATure ImmuNoLogy control the phosphorylation of STAT1 in fibroblasts 32, 33 . We showed that protein tyrosine phosphatases restrained IL-6 signaling through STAT1 in activated and memory CD4 + T cells. Transcriptional profiling of PTP expression in CD4 + T cells identified several candidate enzymes that were induced after CD4 + T N activation, including PTPN2, PTPN22 and DUSP2. Because DUSP2 inhibits signaling through STAT3 and restricts T H 17 differentiation 30 , we assessed whether PTPN2 and PTPN22 affected STAT1 phosphorylation. PTPN2 and PTPN22 inhibited STAT1 activity, but had a less obvious impact on STAT3 activity. This observation might indicate a physical interaction between these PTP and STAT1.
PTPN2 and PTPN22 control various lymphocyte responses, and individuals with genetic polymorphisms in PTPN2 or PTPN22 frequently show increased susceptibility to autoimmune disease 34, 35 . The ability of PTPN2 and PTPN22 to control Jak-STAT signaling may contribute to these outcomes through the control of immune activation, tolerance and autoimmunity. Our data showed that synovial PTPN2 was highly expressed in lymphoid-rich synovitis. This form 
NATure ImmuNoLogy of joint pathology is defined by the presence of functional ectopic lymphoid aggregates within the inflamed synovium 36 . Significantly, PTPN2 has been linked with the regulation of follicular T H cells and the activation of T and B cell responses [37] [38] [39] [40] . Our investigation showed that PTPN2 controlled the expression of genes commonly associated with ectopic lymphoid-like structures. For example, PTPN2 control of STAT1 phosphorylation was shown to affect the transactivation of inflammatory cytokines (for example, IL-17A, IL-21), transcription factors (for example, Bcl6), immune checkpoint regulators (for example, CD274) and homeostatic chemokine receptors (for example, CXCR4, CXCR5) involved in the activity or spatial organization of lymphoid aggregates 36 . The gene signature identified through our screen may therefore predict the efficacy of adoptive immunotherapy and vaccination strategies, or response to biological drug therapies.
ChIP-seq of STAT1 and STAT3 in IL-6-treated CD4 + T N and T EM cells showed that both transcription factors bound to consensus motifs for STAT proteins (for example, ISRE, GAS), and sequences specific for other transcription factors (for example, SP1-like proteins) [41] [42] [43] [44] . While the binding of STATs to these genomic sites requires further analysis, our results suggested that the induction of PTPN2 in activated CD4
+ T cells affected the expression of STAT-regulated genes controlled by P300 enhancer elements. Many of the genes associated with these enhancers were induced by IL-6 in CD4
+ T EM cells and included genes commonly associated with T H 1, T H 2, T H 17 or T FH cells 27, 28 . These activities fit with the capacity of IL-6 to govern CD4 + T cell memory 4, 5, 45, 46 . For example, IL-6 renders antigen-specific T cells refractory to suppression by regulatory T cells 47, 48 . However, IL-6 signaling is not critical for the generation or maintenance of CD4 + memory cells 4, 6 . Instead, our data revealed that IL-6 promotes the effector or functional characteristics of CD4 + T EM cells. This contrasts with the activities of IL-23, which regulates memory recall through the control of cell-cycle progression and proliferation 7, 49, 50 . Thus, PTPN2 control of STAT1 may support CD4 + T cell memory responses by shaping effector memory functions or prolonging lymphocyte survival. Such findings may be relevant to our understanding of how T cells become released from anergy and might explain how T cells become directed down a commitment pathway as a response to specific TCR antigens 39, 51, 52 .
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Methods
Recombinant cytokines. Recombinant mouse IL-6 (IL-6), IL-27, IL-10, IL-7 and IFNγ were purchased from R&D Systems. The IL-6-sIL-6R fusion protein HDS (MW: 63.5 kDa) was expressed in CHO cells and purified through a partnership with the CRO Biovian OY (Turku, Finland). HDS was engineered by coupling the entire coding sequence (amino acid residues 1-364) for the differentially spliced variant of human IL-6R (containing the unique COOH-terminal amino acid sequence: GSRRRGSCGL) to IL-6 (amino acid residues 29-212) via a flexible glycine-serine-rich linker sequence (single amino sequence: GGGGSGGGGSLE) 8 .
Antibodies. Mouse-specific antibodies to CD3ε/γ (17A2; BioLegend), CD4 (RM4-5; eBioscience), CD25 (PC61.5; eBioscience), CD44 (IM7; BD Biosciences), CD62L (MEL-14; Life Technologies), CD126 (D7715A7; eBioscience), CD127 (25-1271-82; eBioscience), βTCR (H57-597), gp130 (125623; R&D Systems), IFNγ (XMG1.2; eBioscience), IL-4 (11B11; eBioscience), IL-17A (TC11-18H10.1; BioLegend), IL-21 (recombinant mouse IL-21R Fc chimera protein; R&D and IL-21 receptor antibody; Jackson Immuno Research) and PTPN2 (AF1930; R&D) were used. For detection of human antigens, we used antibodies specific to CD3 (UCHT1; BioLegend), CD4 (RPA-T4; eBioscience), CD45RA (HI100; BioLegend), CD45RO (UCHL1; BioLegend), CD62L (DREG-56; BD Biosciences), CD197 (CCR7; G043H7; BioLegend). Human and mouse cross-specific antibodies to pY-STAT1 (pY701; 4a), pY-STAT3 (pY705; 4/P-STAT3), pS-STAT1 (pS727; K51-856) and pS-STAT3 (pS727, 49/p-Stat3) were from BD Biosciences.
Mice. Inbred wild-type C57BL/6 male mice were purchased from Charles River UK. C57BL/6 IL-6 receptor-deficient mice (Cd126 . All procedures were performed in accordance with the NHMRC Australian Code of Practice for the Care and Use of Animals and approved by the Peter MacCallum Animal Ethics and Experimentation Committee (ethics number: AEEC 570). Antigen-induced arthritis was performed under the UK Home Office-approved project licenses PPL 30/2928 and PB3E4EE13 as previously described 53 . Briefly, mice were immunized (subcutaneously (s.c.)) with 100 µl mBSA (1 mg/ml emulsified in Complete Freund's Adjuvant; CFA) and 160 ng Bordetella pertussis toxin (intraperitoneally (i.p.)) (all from Sigma-Aldrich). Mice were administered with mBSA and CFA (s.c.) one week later. Inflammatory arthritis was triggered 21 d after the initial immunization by intra-articular administration of mBSA (10 µl; 10 mg/ml) into the right knee joint. Animals were monitored daily for well-being and clinical signs of arthritis and killed at indicated time points for evaluation of joint-infiltrating T cells by flow cytometry and immunofluorescence. For flow cytometric analysis of synovial CD4 + T cells, inflamed synovium was first dissected and digested in collagenase type IV (37 °C, 1 h) before being passed through a 40 µm cell strainer to generate single-cell suspensions.
Human synovial samples. Synovial samples were acquired through a minimally invasive ultrasound-guided synovial biopsy (see ref. ) T cells using a BD FACS ARIA III (BD Biosciences). T cell subset purity was >98%. Naïve CD4 + T cells were cultured in RPMI-1640 supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate and 50 µM 2-mercaptoethanol. 1 × 10 5 CD4 T cells were activated by plate-bound anti-CD3 (1 μg/ml; 145-2C11, R&D Systems) and soluble anti-CD28 (5 μg/ml; 37.51, eBioscience). Where indicated, CD4 + T cells were rested for 48 h in the absence of stimulatory antibodies or cytokines (Supplementary Fig. 2a ). CD4 + T cells from the inguinal lymph nodes of mBSA-immunized and non-immunized mice were derived using a CD4 + T cell isolation kit (Miltenyi Biotec) and treated with IL-6 for 30 min with anti-CD3/CD28 stimulation. Human peripheral blood mononuclear cells (PBMC) were isolated from fresh whole blood as previously described 56 . Naïve (CD3 Histological analysis. Formalin-fixed paraffin-embedded knee joints from AIAchallenged mice were prepared for immunofluorescent and immunohistochemical detection of antigens as described previously 53 . For immunofluorescence, sections were rehydrated, and antigen retrieval was performed in 10 mM sodium citrate buffer containing 0.05% (v:v) Tween-20 (95 °C, 40 min). Sections were incubated with 10% (v:v) goat or swine serum appropriate to the secondary antibody. Cells positive for CD3 and intracellular phospho-STAT1 and STAT3 were detected using CD3 (A0452, Dako), and pY-STAT1 (Tyr701; 58D6) or pY-STAT3 (Tyr705; D3A7) specific antibodies from Cell Signaling Technologies. For CD3 staining, primary antibody detection was performed using biotinylated swine anti-rabbit IgG (E0431, Dako) with streptavidin-APC (BD Biosciences). For pY-STAT1 and pY-STAT3 detection, a secondary rabbit anti-goat IgG Alexa Fluor 488 (Life Technologies) was used. Slides were mounted with Prolong Gold Antifade with DAPI nuclear counterstain (Invitrogen). Images were collected using a Zeiss Apotome microscope and analyzed using ImageJ software. For immunohistochemistry, antigens were detected in paraffin sections using antibodies to CD3 (A0452, Dako), pY-STAT1 (Tyr701; 58D6) and PTPN2 (AF1930, R&D Systems). Antigen retrieval was performed as described above, and endogenous peroxidase activity was blocked using 3% (v:v) H 2 O 2 . Antibody labeling was detected using biotinylated secondary antibodies (Dako, E0431), the Vectastain ABC kit and diaminobenzidine (Vector Laboratories). Sections were counterstained with hematoxylin. Images were collected using Leica DM 2000 Led and quantification of staining performed using the Leica QWin microscope imaging software.
Flow cytometry. Analysis was performed as described previously 7, 8, 15 . For the intracellular detection of STAT1 and STAT3 phosphorylation, purified CD4 + T cells were fixed in 2% (w:v) paraformaldehyde for 15 min at 37 °C, then permeabilized in 90% (v:v) methanol at -20 °C for 3 h. Cells were stained for CD4 and phosphorylated STAT1 and STAT3 (ref. 7 ). To evaluate effector cytokine production, CD4
+ T cells were stimulated with 50 ng PMA (phorbol 12-myristate 13-acetate), 500 ng ionomycin and 3 μM monensin for 4 h prior to flow cytometric analysis 7, 8, 15 . Cells were acquired on a CyAn ADP analyzer (Beckman-Coulter) and analyzed using Summit (software v4.3, Beckman-Coulter) or FlowJo 10 (TreeStar). For imaging flow cytometry, cells were resuspended in 100 µl of PBS and acquired using the ImageStream imaging flow cytometer (Amnis). For colocalization analysis, ImageStream software IDEAS (Amnis) was used.
RNA purification and qPCR. For quantitative real-time PCR (qPCR) and Affymetrix gene chip analysis, total RNA was extracted from purified or cultured CD4 + T cells using the RNeasy Mini Kit (Qiagen) and QIAshredders (Qiagen). Contaminating genomic DNA was removed by means of on-column DNase digestion (Qiagen). RNA was converted to cDNA using the High Capacity cDNA Reverse Transcription Kit with RNase Inhibitor kit (Life Technologies). Gene expression was determined via qPCR 8, 57 , using the QuantStudio 12K Flex Real-Time PCR system and the following TaqMan probes from Thermofisher:
and Actb (Mm01205647_g1) as a housekeeping gene. Relative mRNA expression was determined using the comparative cycle threshold (CT) method and normalized to the gene Actb.
Affymetrix microarray and transcriptomic analysis. Purification of high-quality RNA (RNA integrity number >8.5) was confirmed using Agilent RNA Nano microfluidic chips using a 2100 Bioanalyzer Instrument (Agilent Technologies). Expression profiling was performed in triplicate using Affymetrix Mouse GeneChip 2.0ST microarrays (Affymetrix). Single-stranded cDNA was synthesized using the Ambion WT (Whole Transcript) Expression Kit with the Affymetrix GeneChip Poly-A RNA Control Kit and Terminal Labelling kit. Arrays were scanned using the GeneChip Scanner 3000 7G (Affymetrix). Raw Affymetrix data files (CEL files) were imported into an in-house analysis pipeline written in R (version 3.1.1) using Bioconductor packages, namely limma, affy and oligo 47, 48, 58, 59 . Data were background corrected, log 2 transformed and quantile normalized using the oligo package (RMA) 'best practice' . Differentially expressed genes and transcripts were identified using the limma package 'best practice' workflow, and P values were corrected via multiple testing using Benjamini-Hochberg (false discovery rate) 48 . Bespoke coding (Perl) (code available on request) was used to unite data over all conditions. To identify differentially expressed genes over all experiments, we selected the genes that were classified as having altered expression (either increasing or decreasing) by a difference of 1.5-fold or greater, with a significant value P ≤ 0.05 and a minimal expression value of 150 relative intensity units. Only transcripts fulfilling all of these selection criteria in three independent microarray experiments were included in the analysis. Files were also created in the input format required for molecular and pathway analysis using Metacore integrated software suite (Thomson Reuters) 59 and Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/products/ipa). Transcriptome matrix visualization and Articles NATure ImmuNoLogy hierarchical clustering were performed using Morpheus software (https://software. broadinstitute.org/morpheus/). Circos plots were obtained using the Circos software (http://circos.ca/software/) 60 . Networks were visualized and analyzed using the open sourced program Gephi (0.9.1) (https://gephi.org/). Microarray data have been deposited in ArrayExpress under accession code E-MTAB-7682.
RNA-sequencing. Open access datasets from IL-6-treated Stat1
−/− and Stat3
−/−
T cells (GSE65621) were obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house bioinformatic pipeline. Briefly, RNAseq single-end fastq files were mapped to mouse assembly GRCm38 using STAR 61 . Transcript counts were produced with FeatureCounts 62 , and data normalized using the Bioconductor package, DeSeq2 (ref. 63 ) obtaining gene expression values as FPKM (fragments per kilobase million).
For the human samples, RNA from homogenized synovial tissue was extracted in Trizol. 1 μg total RNA was used as input material for library preparation using TruSeq RNA Sample Preparation Kit v2 (Illumina). Generated libraries were amplified with ten cycles of PCR. Library size was confirmed using 2200 TapeStation and High Sensitivity D1K screen tape (Agilent Technologies) and concentration was determined via a qPCR-based method using Library quantification kit (KAPA). Libraries were multiplexed (five per lane) and sequenced on Illumina HiSeq2500 (Illumina) to generate 50 million paired-end 75-base-pair reads. Transcript abundance was derived using Kallisto v0.43.0 with GENCODE v24/GRCh38 as reference 64 . Transcript abundances were summarized over transcript isoforms using Bioconductor package tximport 1.4.0. Imported abundances were processed using DESeq2 1.14.1 and transformed as regularized log expression (RLE). Statistical analysis of gene-gene correlations was performed using Pearson correlation. P values were adjusted using FDR correction (Benjamini-Hochberg). RNA-seq data have been deposited in ArrayExpress under accession code E-MTAB-6141.
Chromatin immunoprecipitation sequencing. STAT1 and STAT3 chromatin
Immunoprecipitation was performed as previously described 20 . Briefly, 1 × 10 7 naïve (T N ) and effector memory (T EM ) CD4 + T cells were activated for 1 h with 20 ng/ml IL-6 in the presence of antibodies to CD3 and CD28 (as described previously). Genomic DNA was extracted, cross-linked and fragmented via sonication prior to overnight incubation with 5 μg of anti-STAT1 (sc-592, Santa Cruz Biotechnology) or anti-STAT3 (sc-482, Santa Cruz Biotechnology) antibodies. The quality of the immunoprecipitation was confirmed by ChIPqPCR for Irf1 and Socs3. To minimize systematic biases in the downstream data, an input reference control sample (chromatin taken before ChIP) was used to correct for genomic copy number variations, sonication-induced fragmentation bias and chromatin accessibility. ChIP-seq libraries for Ion Torrent sequencing were prepared according to manufacturer's instructions (# 4473623, Ion ChIP-Seq Library Preparation on the Ion Proton TM System). Briefly, DNA fragments were end-repaired and ligated to ion-compatible adapters. Libraries were amplified and size-selected for insert lengths of approximately 100-250 bp. Between 40 M to 70 M reads were obtained for each sample and mapped to Murine Genome Build GRCm38 (mm10) using the Ion Proton recommended mapper Bowtie2 (refs. 65, 66 ). Reads were removed where mapping quality was less than q20 (phred score), and peaks were called using HOMER (Hypergeometric Optimization of Motif EnRichment). To identify putative peaks in both ChIP and input, we first used HOMER findPeaks with a FDR of 0.05. To identify sample peaks in the context of input, we then used HOMER findPeaks with the default parameters (fold change >4-fold, P < 0.0001). Peaks were visualized using Integrative Genomics Viewer (IGV 2.3.88, ref. 67 ). Available p300 ChIP-seq fastq files from CD4 + T cells, T H 1, T H 2 (GSE40463) and T H 17 (GSE60482) were obtained from GEO (https://www. ncbi.nlm.nih.gov/geo/) and aligned and processed using an in-house pipeline. Reads were mapped to the same mm10 assembly using BWA. All reads with a mapping quality less than q20 were removed. HOMER software was used to locate P300 enhancer elements (using the Homer option, -style super) and parameters fold change >2-fold, P < 0.0001. To align STAT1 or STAT3 peaks with SE regions, overlapping loci identified by STAT1 and STAT3 ChIP-seq and p300 ChIP-seq were identified using bedtools (http://bedtools.readthedocs.io/en/latest/) 68 . ChIP-seq data have been deposited in ArrayExpress under accession code E-MTAB-6273.
ChIP-qPCR.
To validate STAT binding to promoter regions, Taqman custom assays were designed (oligonucleotide primer sequences in Supplementary Table 2) and qPCR performed using a QuantStudio 12K Flex Real-Time PCR System. For analysis of SP1, chromatin immunoprecipitation was conducted as previously described using 5 μg of SP1 antibody (#17-601, Millipore) or isotype-specific IgG control. Analysis via qPCR used oligonucleotide primer sequences to the promoter regions of Irf1, Socs3, Stat3, Cd274, Il4ra, Junb and Socs1 (Supplementary Table 2 ). Specific enrichment was normalized by subtracting the IgG control values from those derived for the input and antibody-specific immunoprecipitation samples. Value were expressed as 2^Δ CT .
Motif finding. MEME Suite 4.11.2 software was used to discover de novoenriched DNA consensus sequences present in peaks identified within the STAT1 or STAT3 ChIP-seq datasets. All sequence predictions derived from MEME based on the interaction of known transcription factors with target DNA sequences were substantiated using STAMP 69 (http://benoslab.pitt.edu/stamp/) and JASPAR database (http://jaspar.genereg.net/cgi-bin/jaspar_db.pl) 70 .
Statistics.
To determine the statistical significance of differences between datasets, two-tailed unpaired Student's t test was performed when two populations were compared. One-way ANOVA followed by Tukey's comparison test was used for multiple comparisons, unless otherwise specified, conducted using GraphPad Prism 5 (GraphPad Software). Statistical significance: *P < 0.05; **P < 0.01; ***P < 0.001, ****P < 0.0001. P ≤ 0.05 was considered significantly different.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Microarray, ChiP-seq and RNA-seq data have been deposited in ArrayExpress under accession codes E-MTAB-7682, E-MTAB-6273 and E-MTAB-6141, respectively. Available p300 ChIP-seq fastq files from CD4 T cells, Th1, Th2 (GSE40463) and Th17 (GSE60482), and Stat1 −/− and Stat3 −/− T cells (GSE65621) were obtained from GEO (https://www.ncbi.nlm.nih.gov/geo/). Access to interactive datasets can be found at www.jones-cytokinelab.co.uk (addition information in relevant figure legends).
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Statistics
For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
The statistical test(s) used AND whether they are one-or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted 
Data
Policy information about availability of data All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
-Accession codes, unique identifiers, or web links for publicly available datasets -A list of figures that have associated raw data -A description of any restrictions on data availability -The data sets generated during the current study for Mircoarray data are available in ArrayExpress: https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-7682
-The data sets generated during the current study for ChIP-seq are available in ArrayExpress: https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6273 Username: Reviewer_E-MTAB-6273 Password: 7tBavowV -Other datasets used for the analysis are available in GEO: GSE40463, GSE60482, GSE65621
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Sample size
Sample size were determined through experience : -Microarray data: we have 2 sample per condition. One of them was used for microarray and the other one for qPCR validation.
-ChIP: we have 2 sample per condition. One of them was used for sequencing and the other one for qPCR validation.
For micrroarray and ChIP-seq techniques, qPCR analysis help to correct the biases of the preferences of the biochip and sequencer for certain sequences and for the bioinformatic processes that are used to analyse the data.
-FACs analysis: at least biological triplicates.
-RNA-seq synovial tissue: sample size was determined based on pilot RNA-seq of 29 synovial samples.
Data exclusions Not data excluded
Replication
All attempts at replication were successful. Experiments have been repeated by different authors and in some cases different techniques have been used -e.g., flow cytometry and immunohistochemistry or Chip-seq and ChIP-qPCR.
Randomization Mouse studies -Studies of antigen-induced arthritis were conducted on male mice to ensure optimal priming of the disease model (>98% penetrance). Since the experimental design was not established to compared difference in responses between groups of mice no randomisation was applied.
Human studies -Synovial biopsies were obtained from patients entered into an open-label randomised controlled clinical trial of biological drug intervention. Patients enrolled to the study were stratified according to the synovial pathology, and were randomised to receive specific biological drug therapy after all clinical screening protocols were conducted. Our study was not subject to this randomisation since we were interested in the synovial gene expression profile associated with defined pathotypes prior to drug treatment. These analyses were independent of the biological drug intervention underpinning the wider trial design.
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Mycoplasma contamination
Cell line was used by Biovan company: Biovian facilities are EMA certified and FDA inspected for cGMP production of investigational and commercial products.
Commonly misidentified lines (See ICLAC register)
Animals and other organisms
Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research
Laboratory animals -Inbred 8-10 weeks wild type C57BL/6 male mice were purchased from Charles River UK.
-C57BL/6 IL-6 receptor deficient mice (Il6ra-/-) mice were bred under approved UK Home Office guidelines in Cardiff University. Male mice were used for experiments at the age of 8-10 weeks.
-Ptpn2fl/fl, Lck-Cre:Ptpn2fl/fl, and Ptpn22-/-mice were bred and housed at the Peter MacCallum Cancer Centre (Melbourne, Australia). All male mice were 8-12 weeks of age.
Wild animals
The study did not involve wild animals
Field-collected samples
The study did not involve samples collected from the field Ethics oversight
